A patient recently handed me three separate biological age reports taken within the same month: an epigenetic clock from a mail order kit, a proteomic panel from a longevity clinic, and a biomarker composite from a wearable company's premium tier. The three numbers spanned a range of nearly a decade. He wanted to know which one was right. The honest answer is that none of them is wrong exactly, and none of them is definitively right either, because they are measuring related but distinct biological signals using different reference populations and different underlying assumptions about what aging even is.
This is not a niche curiosity anymore. Biological age testing has moved from an academic research tool into a mainstream consumer category over the past two years, sold through longevity clinics, direct to consumer telehealth platforms, and increasingly through primary care practices trying to differentiate themselves with a wellness offering. The market has expanded faster than the underlying science of cross validating these tests against each other, which means clinicians are now regularly fielding questions from patients holding conflicting numbers with no clear way to reconcile them.
Different clocks measure different things
Epigenetic clocks estimate age from DNA methylation patterns and were originally built and validated against cohort mortality data. Proteomic clocks instead measure patterns across hundreds or thousands of circulating proteins, which can pick up signals related to organ specific aging that a methylation clock will not capture in the same way. Composite biomarker scores, the kind built into some wearable and telehealth platforms, typically combine a handful of standard clinical labs, such as inflammatory markers, lipid panels and metabolic indicators, into a single index using a proprietary weighting formula that is rarely published in enough detail for outside researchers to independently validate.
Each approach has a plausible scientific rationale and each has published correlations with mortality or disease risk in specific study populations. The problem is that these populations differ, the assays differ, and the resulting scores are not built to be interchangeable. A person can reasonably score younger on one clock and older on another simply because the two tools are sensitive to different aspects of physiology, not because one test is defective and the other is accurate.
Why discordance is a business problem as well as a scientific one
For companies selling these tests directly to consumers, discordance between competing products is becoming a credibility risk that the category cannot keep deferring. A customer who buys two different biological age tests in the same year and gets two meaningfully different answers has a reasonable basis to distrust both, and word of that kind of experience travels quickly among the exact demographic most likely to spend on repeat testing. Some longevity clinics have responded by standardising on a single test they can explain clearly to patients rather than offering a menu of assays with no framework for interpreting disagreement between them.
A handful of research groups have begun publishing comparative studies that test multiple clocks against the same blood draw in the same cohort, and the early pattern is instructive: correlation between different clock types tends to be modest rather than strong, even though each clock individually correlates reasonably well with age and, in some cohorts, with future health outcomes. That combination, moderate agreement with each other but real predictive value individually, is difficult to communicate to a consumer audience that wants a single trustworthy number rather than a nuanced statistical picture.
Toward a more honest testing category
The direction the field most plausibly needs is not a single winning clock but clearer labelling of what each test actually measures and what it has been validated against. A methylation based clock validated primarily against smoking status and body mass index in a research cohort is a different product, in practical terms, from a proteomic panel validated against cardiovascular outcomes in a clinical population, even if both are marketed under the same "biological age" banner. Regulatory and professional bodies focused on laboratory developed tests have begun paying closer attention to how these products are marketed, particularly where claims edge toward implying a validated clinical use rather than a wellness estimate.
For clinics and platforms building around these tools, the more defensible long term position is to be explicit with patients about what a given test does and does not capture, to avoid implying interchangeability between assay types, and to use repeat testing with the same assay over time as the primary clinical value, rather than treating a single cross sectional score as a verdict. That approach sacrifices some of the marketing simplicity of a single definitive number, but it is closer to what the underlying evidence actually supports.
Key Signals
The rapid commercial expansion of biological age testing has outpaced the field's work on cross validating different assay types against each other, leaving patients with genuinely discordant results and no standard framework for reconciling them. Epigenetic, proteomic and composite biomarker clocks are built on different biological signals and different validation cohorts, so disagreement between them reflects measurement diversity rather than simple error in any one test. This discordance is increasingly a commercial liability as well as a scientific limitation, since consumers who receive conflicting numbers from competing products have good reason to question the category's overall credibility. The most defensible near term path for clinics and vendors is transparent labelling of what each test measures and disciplined use of longitudinal tracking with a single consistent assay, rather than marketing any individual score as a definitive verdict on a person's aging rate.
